Investing in psychedelic stocks today could be like getting in on the ground floor of the medical marijuana industry.
Investors who think they missed the explosion in pot stocks in 2018 need not worry.
Right now, there are newly legal, early-stage psychedelic medicine companies conducting trials that most of Wall Street is completely missing… Just like people weren’t sure if marijuana had any medical benefits back in 1996, microdoses of magic mushrooms, LSD, ketamine, MDMA, and DMT are now being tested for medical benefits of their own.
These studies have FDA approval.
That means there is a real possibility some companies will win federal approval to sell these drugs.
And that’s creating a brand-new opportunity for investors to get in on the ground floor of these psychedelic stocks… .